Adoption of international good manufacturing practices in the Nigerian pharmaceutical industry: promising results from a decade of investment
Collaboration among NAFDAC, local manufacturers, the WHO PQ Team, and other partners enabled successful implementation of these programs, culminating in WHO PQ of Swiss Pharma Nigeria Limited's zinc sulfate dispersible tablets on June 6, 2023 - the first in West Africa. However, significant challenges persist, including insufficient understanding of WHO PQ requirements, inadequate GMP-compliant facilities, and financial constraints. Addressing these issues requires targeted interventions focused on GMP awareness, infrastructure investment, regulatory support, and harnessing Nigeria's potential as a pharmaceutical manufacturing hub.
Authors
- Jonathan Ukwuru
- Kwasi Poku Boateng
- Mopa Esuga
- Abbas Aliyu Sambo (ORCID: https://orcid.org/0009-0006-2977-4968)
- Obinna Ikechukwu Ekwunife (ORCID: https://orcid.org/0000-0003-0879-3861)
- Uzoma Ezeoke
- Frank Monemeh
- Olakunle Ekundayo
- Jude Nwokike
- Moji Adeyeye
- Anthony Longe
- Emmanuel Ogwuche
- Nenye Njoku
Institutions
- Pharmaceutical Research and Manufacturers of America (US)
- United States Agency for International Development (US)
- United States Pharmacopeial Convention (US)
- Indian Drugs and Pharmaceuticals Limited (IN)
- PharmaSuisse (CH)
- Food and Drug Administration (TH)
- Teva Pharmaceuticals (Czechia) (CZ)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1080/20523211.2025.2597561
- Primary Topic
- Pharmaceutical Quality and Counterfeiting
- Type
- article
- Field-Weighted Citation Impact
- 0.00